ClinicalTrials.gg
Not yet recruitingNCT06063733Updated Oct 2, 2023

Development and Feasibility Testing of Digital Theory-based Pursed Lip Breathing in Stable Patients With COPD

An interventional study of Digital pursed lip breathing intervention in Pulmonary Disease, Chronic Obstructive, sponsored by Manchester Metropolitan University. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-10-02.

Sponsored by Manchester Metropolitan University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
270th of 289
15 · median 160
Started
2023
with 44 others
No phase
121 of 407
32 open now
Primary completion
2024-04
later than 7 of 127 live
Registered
270th of 407
by date

Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 270th largest by planned enrollment of the 289 interventional ones that give a count, is one of 45 that started in 2023, is one of 121 with no phase, reaches primary completion later than 7 of the 127 other live ones, and was the 270th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The goal of this pre-post design clinical trial is to develop a digital, theory-based Pursed Lip Breathing intervention protocol software system installed on smartphones (DT-PLB) and to preliminarily evaluate its feasibility and effects in stable Chronic Obstructive Pulmonary Disease (COPD). The main objectives are:

  1. To develop a digital, theory-based Pursed Lip Breathing intervention protocol software system installed on smartphones for managing breathing exercises in stable COPD patients.
  2. To pilot the methodological procedures of the pre-post study.
  3. To determine the recruitment rate, retention rate, attrition rate, and software usage compliance during the subject recruitment and follow-up process of the pre-post study.
  4. To evaluate the perception and satisfaction of COPD patients using the DT-PLB.
  5. To preliminarily examine the effects of using the DT-PLB intervention on COPD patients, including the six-minute walking test, FEV1% predicted, FEV1/FVC, mMRC scale, COPD assessment test scale, and health points.
  6. To identify any potential adverse events associated with the implementation of DT-PLB.

Participants will perform the following tasks during the intervention:

  1. Register a personal account on the DT-PLB software.
  2. Acquire knowledge and skills related to Pursed Lip Breathing by watching instructional videos.
  3. Practice Pursed Lip Breathing for 10 minutes per session, three times daily for eight weeks, as per reminders and guidance provided by the software.
  4. Earn health points by completing specific actions as instructed.
  5. Optionally post individual texts on the peer forum for peer support within the DT-PLB software.
  6. Complete two outcome assessments as scheduled.
03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Pursed lip breathing
  • Behavioral interventions
  • Gamification
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with satisfying GOLD criteria (Agusti, 2022) ;
  • Being Chinese;
  • Able to understand, speak, and hear;
  • Clinically stable for at least three months prior to enrollment (Soler-Cataluna et al., 2018) ;
  • The classification of GOLD grades for patients is mild, moderate, and severe, which means: /FVC\<70%, FEV1>30%pre (Agusti, 2022) ;
  • Participants who were mindful about the IT technology and known how to use a smartphone.

Exclusion criteria

Exclusion Criteria:

  • Impaired hand function causing inability to use the application;
  • Have disorders in pleural effusion, pulmonary , heart diseases, stroke with sequels;
  • Patients who have oral or nasal diseases cannot complete the exercise.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Digital PLB intervention

    Participants will perform the following tasks during the intervention: 1. Register a personal account on the theory-based pursed lip breathing intervention protocol software system installed on smartphones(DT-PLB). 2. Acquire knowledge and skills related to pursed lip breathing by watching instructional videos. 3. Practice Pursed Lip Breathing for 10 minutes per session, three times daily for eight weeks, as per reminders and guidance provided by the software. 4. Earn health points by completing specific actions as instructed. 5. Optionally post individual texts on the peer forum for peer support within the DT-PLB software. 6. Complete two outcome assessments as scheduled.

    Other: Digital pursed lip breathing intervention

Interventions

  • OtherDigital pursed lip breathing intervention

    After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks. After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments. Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities.

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    The number of participants who participate in the study divided by the number of participants eligible for participation

    Time frame: From baseline (T1) to the completion of the 8-week intervention (T2)

  2. Retention rate

    The number of subjects who complete the study divided by the number of subjects who participate in the study

    Time frame: From baseline (T1) to the completion of the 8-week intervention (T2)

  3. Attrition rate

    The number of subjects who drop out after participation divided by the number of subjects who participate in the study

    Time frame: From baseline (T1) to the completion of the 8-week intervention (T2)

  4. Software usage Compliance

    The compliance rate is one of compliance outcomes, reflecting the level of patient engagement in the intervention. Overall compliance will be defined as the compliance averaged in all patients. Compliance rate = (actual number of participation in the intervention/planned number of sessions)x 100%. In addition, minutes-consuming recorded on the software for participants during the research will be used to complement outcome measures of compliance.

    Time frame: Immediately after completion of the 8-week intervention

  5. Adverse events associated with the DT-PLB intervention

    In each DT-PLB session, the participants during the intervention will record whether they had any uncomfortable feelings

    Time frame: Immediately after completion of the 8-week intervention

Secondary outcomes

  1. mMRC Dyspnea Scale

    The Modified Medical Research Council (mMRC) Dyspnea Scale consists of five categories, ranging from 0 to 4, with higher scores indicating more severe breathlessness. A score of 0 indicates no breathlessness during activities, while a score of 4 suggests breathlessness.

    Time frame: From baseline (T1) to the completion of the 8-week intervention (T2)

  2. CAT scale

    COPD assessment test (CAT)is a questionnaire-based tool that is commonly used to assess the impact of chronic obstructive pulmonary disease (COPD)on a patient's health status and quality of life. It consists of eight questions that cover a range of symptoms, including cough, sputum production, breathlessness, chest tightness, and activity limitations. Each question on the CAT is scored on a scale from 0 to 5, with a maximum possible score of 40. A higher score indicates a greater degree of symptom severity and a poorer health status.

    Time frame: From baseline (T1) to the completion of the 8-week intervention (T2)

  3. The System Usability Scale

    The system usability scale (SUS)is a standardized questionnaire that is used to evaluate the usability and user experience of a wide range of products, services, and systems. It produces a score between 0 and 100, with higher scores indicating better usability and user experience. The SUS has been validated and is widely used in both industry and research settings to evaluate the usability and user experience of a wide range of systems and products, including software applications, websites, and medical devices.

    Time frame: Immediately after completion of the 8-week intervention (T2)

  4. Participants overall satisfaction

    Participants will be required to rate their satisfaction with this software intervention, with a 10-point numeric rating scale (NRS) , where "1" represents "very dissatisfied" and "10" means "very satisfied".

    Time frame: Immediately after completion of the 8-week intervention (T2)

  5. Six-minute-walking test

    The Six-Minute Walk Test is a commonly used measure of functional exercise

    Time frame: From baseline (T1) to the completion of the 8-week intervention (T2)

  6. Pulmonary function index:FEV1%predicted, FEV1/FVC

    FEV1%predicted stands for "forced expiratory volume in one second predicted" and is a measure of lung function. It represents the maximum amount of air that a person can forcefully exhale from their lungs in one second. FEV1%predicted is expressed as a percentage of the predicted value for someone with the same characteristics who does not have lung disease. FEV1/FVC is another measure of lung function, which represents the ratio of the amount of air that a person can forcefully exhale in one second (FEV1)to the total amount of air that they can exhale(forced vital capacity or FVC)over the course of a full exhalation. A low FEV1/FVC ratio indicates that the airways are obstructed or narrowed, which is a characteristic feature of COPD.

    Time frame: From baseline (T1) to the completion of the 8-week intervention (T2)

  7. Health points obtained by each participant performing formulated operations

    Health points are set based on consensus, obtained by operating actions on this software: 1. Login: participants' stay on the software lasts for over one minute, they will earn one health point, with a maximum of three health points per day. 2. Watch PLB health education video: For every minute participants stay on the video, they will earn one health point. The maximum score for a single viewing is equal to the length of the video. 3. Accept PLB exercise task: Earning one health point upon claiming an exercise task. For every minute spent on the exercise animated videos, patients earn one health point, with a maximum of up to ten health points. 4. Social forum: Participants can post an update in an internal forum, earning them one health point, with a maximum of three health points per day. 5. Reward health points of consecutive accepted tasks: an additional rewarded 50 points for continuously claiming exercises tasks for 9 consecutive times.

    Time frame: Immediately after completion of the 8-week intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Apr 2024, 5 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Oct 2, 2023
StartEst.
Oct 30, 2023
Primary completionEst.
Apr 20, 2024
CompletionEst.
Apr 20, 2024
Last update
Oct 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063733
Lead sponsor
Manchester Metropolitan University
Responsible party
Houqiang Huang (A postgraduate researcher in the School of Nursing & Public Health, Manchester Metropolitan University) — Principal investigator
First posted
Oct 2, 2023
Start date
Oct 30, 2023 (estimated)
Primary completion
Apr 20, 2024 (estimated)
Completion
Apr 20, 2024 (estimated)
Last update
Oct 2, 2023

Study contacts

Houqiang Huang, Master
Contact
21442584@stu.mmu.ac.uk
+8618715799162
Houqiang Huang, Master
principal investigator · Manchster Metropolitan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion